Cardiff Oncology, INC Form 4 insider transactions

Gary W Pace, a Director of Cardiff Oncology, Inc., purchased 1,374,570 shares of common stock on July 14, 2026 for $1.46 per share.

Mani Mohindru, Chief Executive Officer and a Director of Cardiff Oncology, Inc., purchased 68,728 shares of common stock on July 14, 2026 for $1.46 per share.

Director James O. Armitage was granted 40,565 stock options in Cardiff Oncology, Inc. as part of a standard equity compensation arrangement.

Director Lale White was granted 40,565 stock options in Cardiff Oncology, Inc. as part of a standard equity compensation arrangement.

Director Renee P. Tannenbaum was granted 40,565 stock options in Cardiff Oncology, Inc. as part of a routine equity compensation.

Cardiff Oncology director Gary Pace was granted 40,565 stock options as part of a routine equity compensation arrangement.

Director Rodney S. Markin was granted 40,565 stock options in Cardiff Oncology, Inc. as part of a standard equity compensation update.

Cardiff Oncology Chief Operating Officer Ajay Aggarwal was granted 400,000 stock options with an exercise price of $1.72.

Cardiff Oncology CFO Joshua Muntner was granted 486,650 stock options as part of an equity compensation package.

Chief Scientific Officer Tod Smeal was granted 300,000 stock options in Cardiff Oncology, Inc. as part of an equity incentive.

Cardiff Oncology CFO Joshua Muntner was granted 486,650 stock options as part of an equity compensation package.

Cardiff Oncology CEO Mani Mohindru was granted 600,000 stock options with an exercise price of $1.62.

Cardiff Oncology Director Gary W. Pace disclosed a future planned acquisition of 290,000 shares of common stock at $2.45 per share, set for July 30, 2025, under a Rule 10b5-1 plan.

Cardiff Oncology, Inc. Director Renee P. Tannenbaum acquired 40,565 stock options with an exercise price of $3.16 per share, signaling increased beneficial ownership.

Cardiff Oncology, Inc. Director Rodney S. Markin was granted 40,565 stock options with an exercise price of $3.16, aligning his interests with shareholder value.

Cardiff Oncology, Inc. Director Mani Mohindru was granted 40,565 stock options with an exercise price of $3.16, exercisable from June 26, 2026, and expiring in 2035.

James O. Armitage, a Director at Cardiff Oncology, Inc., was granted 40,565 stock options with an exercise price of $3.16, as disclosed in a recent SEC Form 4 filing.

Cardiff Oncology, Inc. Director Lale White was granted 40,565 stock options with an exercise price of $3.16, exercisable from June 26, 2026, as part of a Rule 10b5-1 plan.

Cardiff Oncology, Inc. Director Gary W. Pace has reported the acquisition of 40,565 stock options with an exercise price of $3.16, effective June 26, 2025.

James Levine, CFO of Cardiff Oncology, reports the acquisition of stock options.

Fairooz Kabbinavar, Chief Medical Officer of Cardiff Oncology, reports the acquisition of 150,000 stock options on March 11, 2025.

Tod Smeal, Chief Scientific Officer of Cardiff Oncology, reports the acquisition of stock options.

Cardiff Oncology's CEO, Mark Erlander, was granted stock options for 758,400 shares on March 11, 2025, according to a Form 4 filing.

Cardiff Oncology's CFO, James Levine, reports changes in beneficial ownership of common stock due to purchases made by his wife.

Director Renee P Tannenbaum of Cardiff Oncology, Inc. engaged in a transaction involving the purchase and disposal of company stock on December 12, 2024.

Gary Pace, an insider at Cardiff Oncology, reported the purchase of 350,115 shares of common stock and 11,500 shares held by a minor child on December 11, 2024.

Director Lale White reports acquisition of stock options in Cardiff Oncology.

Director Renee P Tannenbaum reports acquiring 29,700 stock options in Cardiff Oncology, Inc. on June 27, 2024.

Director Mani Mohindru reports acquisition of stock options in Cardiff Oncology.

Director Gary W. Pace of Cardiff Oncology, Inc. reports the acquisition of 29,700 stock options on June 27, 2024.